Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.

doi:10.1056/NEJMoa2504059

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.

The New England journal of medicine - 3 Sept 2026

Arbour Kathryn C, Punekar Salman, Luo Jia, Johnson Melissa, Spira Alexander, Herzberg Benjamin, Starodub Alexander, Sommerhalder David, Hecht Joel Randolph, Garrido-Laguna Ignacio, Barve Minal, Ou Sai-Hong Ignatius, Kar Sumit, Bao Lei, Tao Lin, Vora Rashmi, Hegde Aparna, Saltos Andreas, Azad Nilofer S, Hong David S

Abstract excerpt

BACKGROUND: RAS mutations, as a group, are the most common oncogenic drivers of non-small-cell lung cancer (NSCLC), and they occur in approximately 30% of patients. Whether daraxonrasib (RMC-6236) - an oral RAS(ON) multiselective, tri-complex inhibitor of guanosine triphosphate-bound mutant and wild-type RAS protein isoforms - is safe and effective in patients with RAS-mutant NSCLC is unknown. METHODS: In this...

Read the complete abstract on PubMed

Topics

Adult
Aged
Aged, 80 and over
Female
Humans

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Male

Middle Aged

Antineoplastic Agents

Carcinoma, Non-Small-Cell Lung

Dose-Response Relationship, Drug

Lung Neoplasms

Mutation

Piperazines

Proto-Oncogene Proteins p21(ras)

Drug Administration Schedule

Administration, Oral

Response Evaluation Criteria in Solid Tumors

Source

Open in PubMed

Identifiers

PMID: 42685317
DOI: 10.1056/NEJMoa2504059

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 27 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.PMID 42685317Read ↗

Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib.Semantic proximity Read ↗

6MO: Safety and clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC)Semantic proximity Read ↗

[Pharmacological characteristics and clinical study results of the first RAS inhibitor sotorasib (LUMAKRAS®) for non-small cell lung cancer with KRAS G12C mutation].Semantic proximity Read ↗

Adagrasib: a novel inhibitor for KRASG12C-mutated non-small-cell lung cancer.Semantic proximity Read ↗

Efficacy and toxicity of drugs targeting KRASG12C mutation in non-small cell lung cancer: a meta-analysis.Semantic proximity Read ↗

Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.Semantic proximity Read ↗

An updated overview of K-RAS G12C inhibitors in advanced stage non-small cell lung cancer.Semantic proximity Read ↗

FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC.Semantic proximity Read ↗

Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial.Semantic proximity Read ↗

Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial.Semantic proximity Read ↗

KRAS-targeted therapy in the treatment of non-small cell lung cancer.Semantic proximity Read ↗

First Approval of Adagrasib for the Treatment of Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.